83 related articles for article (PubMed ID: 21680189)
1. Synthesis and evaluation of bidentate ligands designed to interact with PDZ domains.
Boucherle B; Vogrig A; Deokar H; Bouzidi N; Ripoche I; Thomas I; Marin P; Ducki S
Bioorg Med Chem; 2011 Jul; 19(14):4346-54. PubMed ID: 21680189
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of PDZ ligands as inhibitors of 5-HT(2A) receptor/PSD-95 PDZ1 domain interaction possessing anti-hyperalgesic activity.
Vogrig A; Dorr L; Bouzidi N; Boucherle B; Wattiez AS; Cassier E; Vallon G; Ripoche I; Abrunhosa-Thomas I; Marin P; Nauton L; Thery V; Courteix C; Lian LY; Ducki S
ACS Chem Biol; 2013 Oct; 8(10):2209-16. PubMed ID: 23895101
[TBL] [Abstract][Full Text] [Related]
3. Identification of PDZ ligands by docking-based virtual screening for the development of novel analgesic agents.
Bouzidi N; Deokar H; Vogrig A; Boucherle B; Ripoche I; Abrunhosa-Thomas I; Dorr L; Wattiez AS; Lian LY; Marin P; Courteix C; Ducki S
Bioorg Med Chem Lett; 2013 May; 23(9):2624-7. PubMed ID: 23545111
[TBL] [Abstract][Full Text] [Related]
4. Binding modes of chain arylpiperazines to 5-HT1a, 5-HT2a and 5-HT7 receptors.
Bielenica A; Kozioł AE; Struga M
Mini Rev Med Chem; 2013 Aug; 13(10):1516-39. PubMed ID: 24568298
[TBL] [Abstract][Full Text] [Related]
5. Rigidified clicked dimeric ligands for studying the dynamics of the PDZ1-2 supramodule of PSD-95.
Eildal JN; Bach A; Dogan J; Ye F; Zhang M; Jemth P; Strømgaard K
Chembiochem; 2015 Jan; 16(1):64-9. PubMed ID: 25407949
[TBL] [Abstract][Full Text] [Related]
6. MAGI proteins can differentially regulate the signaling pathways of 5-HT
Hammad MM; Dunn HA; Ferguson SSG
Cell Signal; 2018 Jul; 47():109-121. PubMed ID: 29625175
[TBL] [Abstract][Full Text] [Related]
7. G protein- and agonist-bound serotonin 5-HT2A receptor model activated by steered molecular dynamics simulations.
Isberg V; Balle T; Sander T; Jørgensen FS; Gloriam DE
J Chem Inf Model; 2011 Feb; 51(2):315-25. PubMed ID: 21261291
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structural investigation of some pyrimido[5,4-c]quinolin-4(3H)-one derivatives with a long-chain arylpiperazine moiety as potent 5-HT(1A/2A) and 5-HT(7) receptor ligands.
Lewgowd W; Bojarski AJ; Szczesio M; Olczak A; Glowka ML; Mordalski S; Stanczak A
Eur J Med Chem; 2011 Aug; 46(8):3348-61. PubMed ID: 21601317
[TBL] [Abstract][Full Text] [Related]
9. An allosteric intramolecular PDZ-PDZ interaction modulates PTP-BL PDZ2 binding specificity.
van den Berk LC; Landi E; Walma T; Vuister GW; Dente L; Hendriks WJ
Biochemistry; 2007 Nov; 46(47):13629-37. PubMed ID: 17979300
[TBL] [Abstract][Full Text] [Related]
10. Detection of new biased agonists for the serotonin 5-HT2A receptor: modeling and experimental validation.
Martí-Solano M; Iglesias A; de Fabritiis G; Sanz F; Brea J; Loza MI; Pastor M; Selent J
Mol Pharmacol; 2015 Apr; 87(4):740-6. PubMed ID: 25661038
[TBL] [Abstract][Full Text] [Related]
11. Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains.
Mayasundari A; Ferreira AM; He L; Mahindroo N; Bashford D; Fujii N
Bioorg Med Chem Lett; 2008 Feb; 18(3):942-5. PubMed ID: 18180157
[TBL] [Abstract][Full Text] [Related]
12. Novel conformational aspects of the third PDZ domain of the neuronal post-synaptic density-95 protein revealed from two 1.4A X-ray structures.
Cámara-Artigas A; Murciano-Calles J; Gavira JA; Cobos ES; Martínez JC
J Struct Biol; 2010 Jun; 170(3):565-9. PubMed ID: 20227506
[TBL] [Abstract][Full Text] [Related]
13. Targeting protein-protein interactions with trimeric ligands: high affinity inhibitors of the MAGUK protein family.
Nissen KB; Haugaard-Kedström LM; Wilbek TS; Nielsen LS; Åberg E; Kristensen AS; Bach A; Jemth P; Strømgaard K
PLoS One; 2015; 10(2):e0117668. PubMed ID: 25658767
[TBL] [Abstract][Full Text] [Related]
14. Solution structure and backbone dynamics of the second PDZ domain of postsynaptic density-95.
Tochio H; Hung F; Li M; Bredt DS; Zhang M
J Mol Biol; 2000 Jan; 295(2):225-37. PubMed ID: 10623522
[TBL] [Abstract][Full Text] [Related]
15. Molecular modeling and docking studies of human 5-hydroxytryptamine 2A (5-HT2A) receptor for the identification of hotspots for ligand binding.
Kanagarajadurai K; Malini M; Bhattacharya A; Panicker MM; Sowdhamini R
Mol Biosyst; 2009 Dec; 5(12):1877-88. PubMed ID: 19763327
[TBL] [Abstract][Full Text] [Related]
16. Overcoming Depression with 5-HT
Zięba A; Stępnicki P; Matosiuk D; Kaczor AA
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008436
[TBL] [Abstract][Full Text] [Related]
17. Creating conformational entropy by increasing interdomain mobility in ligand binding regulation: a revisit to N-terminal tandem PDZ domains of PSD-95.
Wang W; Weng J; Zhang X; Liu M; Zhang M
J Am Chem Soc; 2009 Jan; 131(2):787-96. PubMed ID: 19072119
[TBL] [Abstract][Full Text] [Related]
18. Quantification of PDZ domain specificity, prediction of ligand affinity and rational design of super-binding peptides.
Wiedemann U; Boisguerin P; Leben R; Leitner D; Krause G; Moelling K; Volkmer-Engert R; Oschkinat H
J Mol Biol; 2004 Oct; 343(3):703-18. PubMed ID: 15465056
[TBL] [Abstract][Full Text] [Related]
19. Probing the structure and function of human glutaminase-interacting protein: a possible target for drug design.
Banerjee M; Huang C; Marquez J; Mohanty S
Biochemistry; 2008 Sep; 47(35):9208-19. PubMed ID: 18690705
[TBL] [Abstract][Full Text] [Related]
20. Discovery, structure-activity relationship studies, and crystal structure of nonpeptide inhibitors bound to the Shank3 PDZ domain.
Saupe J; Roske Y; Schillinger C; Kamdem N; Radetzki S; Diehl A; Oschkinat H; Krause G; Heinemann U; Rademann J
ChemMedChem; 2011 Aug; 6(8):1411-22. PubMed ID: 21626699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
